1 / 27

Decision-making on FP7 work programmes and calls

Decision-making on FP7 work programmes and calls. European Commission Research and Inovation DG, Directorate F Health Grigorij Kogan. EKHA Meeting, Brussels 23/01/2012. EU support for Research and Innovation.

nasia
Download Presentation

Decision-making on FP7 work programmes and calls

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Decision-making on FP7 work programmes and calls European Commission Research and Inovation DG, Directorate F Health Grigorij Kogan EKHA Meeting, Brussels23/01/2012

  2. EU supportfor Research and Innovation The €50 billion Seventh Framework Programme (FP7, 2007-2013) supports basic and applied research activities, still far from the market, offers money and concentrates resources on strategic research areas, always on the basis of technological and scientific excellence. The broad objectives of FP7 have been grouped into four categories: Cooperation Ideas People Capacities For each type of objective, there is a specific programme corresponding to the main areas of EU research policy. All specific programmes work together to promote and encourage the creation of European poles of (scientific) excellence

  3. FP7 budget (2007-2013): €55 billion = ~6% of public R&D investment in Europe

  4. Cooperation programme:thematic areas (€32.4 billion)

  5. http://bookshop.europa.eu/eubookshop/publicationDetails.action?pubuid=593335&offset=0http://bookshop.europa.eu/eubookshop/publicationDetails.action?pubuid=593335&offset=0

  6. FP7 Health Programme - structure pillar 3: Optimising the delivery of health care pillar 2: Translating research for human health pillar 1: Biotechnology, generic tools & technologies for health cross-cutting issues: child health, the health of ageing population gender-related health issues Activity (Pillar) 4: Other actions across the theme

  7. Collaborative researchin the Health theme Main policy drivers: • Improving health of European citizens • Increasing competitiveness of European health-related industries and businesses • Addressing global health issues, including emerging epidemics

  8. Collaborative research at European level across borders and other barriers • between countries: • multinational consortia, with at least 3 partners from 27 EU Member States (MS) and / or Associated Countries (AC) e.g.: Albania, Croatia, FYR Macedonia, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey. • researchers from any country in the world can participate, from industrialised countries and from developing countries. e.g.: Argentina, Australia, Brazil, Canada, China, India, Japan, Korea, New-Zealand, Russia, South-Africa, USA… • between different types of organizationsPublic & private sector: universities, research centres, large companies, Small and medium-sized enterprises (SMEs), etc. • between disciplines:multidisciplinary, translational

  9. Collaborative researchin the Health theme 1:Biotechnology, generic tools and technologies • High-throughput research • Detection, diagnosis and monitoring • Predicting suitability, safety and efficacy of therapies • Innovative therapeutic approaches and interventions

  10. Collaborative researchin the Health theme 2:Translating research for human health • Integrating biological data and processes: large-scale data gathering, systems biology • Research on the brain and related diseases, human development and ageing • Translational research in major infectious diseases • Translational research in other major diseases

  11. Collaborative researchin the Health theme 3:Optimising the delivery of healthcare • Translating clinical research into clinical practice • Quality, efficiency and solidarity of healthcare systems • Enhanced health promotion and disease prevention

  12. Collaborative researchin the Health theme 4. Actions across the Theme • Coordination & Support Actions across the theme • Responding to EU policy needs • Specific International Cooperation Actions (SICAs)

  13. FP7 Cooperation Work Programme: Health-2012 07/09/2014

  14. Two-stage submission and evaluation procedureTimetable

  15. Funding schemes in the Health theme Funding schemes limits partners Large-scale integrating project (CP-IP) ≥ €6m ≤ €12m ≥3 Network of Excellence (NoE)≤€12m ≥3 Small- or medium-scale focussed research project (CP-FP) ≤€3m or €6m ≥3 Coordination action (CA)* ≤€1.5m ≥3 Support action (SA)* ≤ €0.5m ≥1 * for CAs and SAs there are some exceptions.

  16. Policy dimensions: Industry (SME) participation & International Cooperation Emphasis and special measures for: • Small & Medium-sized Enterprises (SMEs) • Opportunities and support measures • International Cooperation • the possibility to tackle issues on a global scale • an opportunity to extend networks beyond Europe

  17. Who prepares the work programmes for the Research Priorities • The EU Commission • Collects ideas for the preparation of the annual FP7 work program • Drafts the (annual) FP7 work plans • Within the EU Commission Scientific Officers (SO) are responsible for the preparatory work • Advisory Groups (AG) • Have been set up by the EU Commission for each of the FP7 themes • They provide consistent, consolidated advice for the work program • Members sit on the AG in their personal capacity and do not represent any organisation or country • National Contact Points (NCPs) • Are main providers of advice and individual assistance in all Member States and Associated States • Have been set up by the Member or Associated States so the type and level of services offered may differ from country to country • Programme Committees (PCs) • Play an important role at the end of the preparation process of each work program. • They have to give their approval for all the work programmes that have been prepared by he EU Commission. • Are involved quite early in the preparation process to insure that the preparation procedure works quick and smooth

  18. Scientific excellence at European level From policy to funding the best research projects: • The policy for Health research is described in the FP7 specific programme (available on CORDIS http://cordis.europa.eu/home_en.html) • Each year, a work programme is prepared by the EC, in consultation with a scientific Advisory Group and with the Programme Committee • Through calls for proposals the EC invites researchers from all Europe and beyond to submit their proposals • The very best projects are selected on the basis of evaluation by independent experts (peer review) • After negotiation of a grant agreement, a project is funded for 2-5 years

  19. Submission & evaluation • Basic principles: • annual calls for proposals • eligibility (scope, partners, funding limits, deadline) • evaluation by panels of independent experts • overseen by Independent Observers • 3 criteria: • Science & Technology excellence • Implementation & Management • Potential Impact • feedback: Evaluation Summary Reports (ESRs)

  20. Annual calls for proposals in the Health Theme • 1st call (2007 budget): € 641 million • 2nd call (2008 budget): € 577 million • 3rd call (2009 budget): € 610 million • 4th call (2010 budget): € 660 million • 5th call (2011 budget): € 650 million • 6th call (2012 budget): ~ € 645 million • 7th call (2013 budget): ~

  21. The Innovative Medicines Initiative (IMI):the Largest PPP in Life Sciences R&D http://www.imi.europa.eu/ • Key Concepts Underlying IMI Projects: • Pre-competitive research • Open innovation • Why Public-Private Partnership? • Innovative medicines require in-depth knowledge of disease pathways and molecular targets • Anticipating potential side effects of new drugs is a must • The pharmaceutical industry builds new business models based on collaboration and transparency • Four Calls published since 2008: • 23 projects funded • Over € 450 million committed 21

  22. Coverage of Kidney Diseases in FP7 Pillar IDEAS – ERC (European Research Council): 4 projects with€ 6,813,200 EU Contribution Pillar COOPERATION - HEALTH: 7 projects with € 46,188,148 EU Contribution INFSO: 2 projects with € 8,759,140 EU Contribution Pillar PEOPLE – 13 projects with € 9,872,575 EU Contribution Total EU Contribution - € 71,633,063

  23. Contacts & Information FP7Healthweb site:http://cordis.europa.eu/fp7/health NCPs:http://cordis.europa.eu/fp7/health/support_en.html Registration as anExpert:https://cordis.europa.eu/emmfp7/ FP7 calls:http://cordis.europa.eu/fp7/dc Health projects database:www.healthcompetence.eu SMEsgoHealth:www.smesgohealth.org

  24. The Health Directorate Director – Dr. Ruxandra Draghia-Akli: Medical Research unit (F2) Head of unit: Maria Vidal-Ragout (maria-jose.vidal-ragout@ec.europa.eu) Deputy Head of Unit: Karim Berkouk (karim.berkouk@ec.europa.eu) Infectious Diseases unit (F3) Head of unit: Line Mathiessen (line.mathiessen@ec.europa.eu) Deputy Head of unit: Anna Lönnroth (anna.lonnroth@ec.europa.eu) Avanced Therapies and Systems Medicine unit (F4) Head of unit: Arnd Hoeveler (arnd.hoeveler@ec.europa.eu) Deputy Head of unit: Bernard Mulligan(bernard.mulligan@ec.europa.eu) Personalized Medicine unit (F5) Head of unit: Patrik Kolar (patrik.kolar@ec.europa.eu) Deputy Head of unit: Irene Norstedt(irene.norstedt@ec.europa.eu) Administration & Finance unit (F6)Head of unit: Georgios Zisimatos(georgios.zisimatos@ec.europa.eu) Horizontal Aspects unit (F1) Head of unit: Stéphane Hogan(stephane.hogan@ec.europa.eu)

  25. What is Horizon 2020

  26. THANK YOU FOR YOUR ATTENTION! Grigorij Kogan « Chronic Diseases » Unit F-2 Medical Research Directorate F « Health » DG Research and Innovation European Commission grigorij.kogan@ec.europa.eu

More Related